| Cancer statistics, 2022. | Ca-A Cancer Journal for Clinicians | 2022 | 842 |
| Hallmarks of Cancer: New Dimensions. | Cancer Discovery | 2022 | 285 |
| Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. | Lancet Oncology, The | 2022 | 58 |
| UALCAN: An update to the integrated cancer data analysis platform. | Neoplasia | 2022 | 44 |
| Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. | Journal of Clinical Oncology | 2022 | 42 |
| The role of ROS in tumour development and progression. | Nature Reviews Cancer | 2022 | 39 |
| Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. | Journal of the National Comprehensive Cancer Network: JNCCN | 2022 | 37 |
| Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. | Journal of Clinical Oncology | 2022 | 36 |
| Immune-checkpoint inhibitors: long-term implications of toxicity. | Nature Reviews Clinical Oncology | 2022 | 34 |
| Targeting ferroptosis as a vulnerability in cancer. | Nature Reviews Cancer | 2022 | 31 |
| Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study. | Journal of Clinical Oncology | 2022 | 27 |
| Glioma targeted therapy: insight into future of molecular approaches. | Molecular Cancer | 2022 | 26 |
| Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. | Lancet Oncology, The | 2022 | 25 |
| Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. | Journal of the National Comprehensive Cancer Network: JNCCN | 2022 | 24 |
| Mutations in SARS-CoV-2 variants of concern link to increased spike cleavage and virus transmission. | Cell Host and Microbe | 2022 | 23 |
| Exosomes as a new frontier of cancer liquid biopsy. | Molecular Cancer | 2022 | 23 |
| Exploiting senescence for the treatment of cancer. | Nature Reviews Cancer | 2022 | 23 |
| Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. | Molecular Cancer | 2022 | 22 |
| SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape. | Cell Host and Microbe | 2022 | 22 |
| HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management. | Nature Reviews Clinical Oncology | 2022 | 22 |
| Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. | Journal of the National Comprehensive Cancer Network: JNCCN | 2022 | 20 |
| A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1. | Journal of Clinical Oncology | 2022 | 20 |
| Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations. | Journal of Clinical Oncology | 2022 | 18 |
| Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. | Lancet Oncology, The | 2022 | 18 |
| A novel ferroptosis-related gene signature associated with cell cycle for prognosis prediction in patients with clear cell renal cell carcinoma. | BMC Cancer | 2022 | 17 |
